ClinicalTrials.gg
Status unknownNCT05818917Updated Apr 19, 2023

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of FHND5071 as a Single Agent in Adult Patients With Advanced Solid Tumors

A Phase 1 interventional study of FHND5071 in Advanced Solid Tumors, sponsored by Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.. Status unknown at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-19.

Sponsored by Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2023), so the status shown — last known as Enrolling by invitation — may be out of date.

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jul 2022, registered Mar 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 1, first-in-human, open-label dose-escalation study to determine the MTD and/or recommended Phase 2 dose (RP2D) and assess the DLT of FHND5071. The safety, tolerability, and PK of FHND5071 will be assessed in adult patients with advanced solid tumors.

The total number of evaluable subjects in the study will depend upon the number of dose-escalations necessary. It is estimated that approximately 24 evaluable subjects will be enrolled in the dose-escalation part of this study. This multicenter study will be conducted in the United States.

Dose-escalation of FHND5071 will follow two sequential parts:

  1. a modified accelerated titration design in single subject cohorts with a starting dose level of 40 mg, where the FHND5071 dose would be doubled in each dose cohort until the subject in a current cohort experience a Grade ≥2 adverse event that is at least possibly related to FHND5071 in the opinion of the Investigator and the Medical Monitor;
  2. a modified 3+3 escalation design in cohort of 3-6 subjects, where the FHND5071 dose would be escalated in ≤100% increments determined by the Safety Review Committee (SRC) until 2 of 3 or 2 of 6 subjects experience a DLT. In both parts of dose escalation, FHND5071 will be administered orally once daily (QD) in 28-day treatment cycles.

Escalation cohorts may explore alternative doses or different schedules, if deemed appropriate by the Safety Review Committee.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. is the lead sponsor of 6 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Only the subjects who meet all of the following inclusion criteria are eligible for entry into this study:

  1. The subjects agree and have the ability to comply with the study and follow-up procedures. Before any examination and study, the subjects or their legal guardians shall sign and date a written ;
  2. Age ≥ 18 years old, male or female;
  3. The Performance Status (ECOG PS) score is 0\~1;
  4. The expected survival period is not less than 12 weeks;
  5. Subjects have at least one evaluable lesion according to V1.1. Tumor lesions that have progressed after being irradiated ≥4 weeks before the start of treatment can be used as target lesions in the absence of non-irradiated evaluable lesions;
  6. Subjects with advanced solid tumors confirmed by histology or cytology, for whom the standard treatment has failed, or there is no standard treatment regime, or the standard treatment is not applicable at the current stage;
  7. Subjects must have adequate organ functions, as defined below:

    Liver function:

    •Serum (AST), serum alanine aminotransferase (ALT) ≤ 2.5 times the (ULN); total serum (TBIL) ≤ 1.5 times ULN (for subjects with Gilbert syndrome, serum bilirubin ≤ 3.0 × ULN).

    Bone marrow function (no blood transfusion or hematopoietic stimulating factor therapy within 10 days prior to testing):

    • (ANC) ≥1.5×109/L;
    • (PLT) ≥100×109/L;
    • (Hb) ≥9g/dL;
    • Lymphocyte count ≥0.5×109/L.

    Kidney function:

    •Serum creatinine ≤1.5 mg/dL, or estimated ≥60 mL/min/1.73m2 using the Chronic Kidney Disease Epidemiology Partnership (CKD-EPI) formula;

    Coagulation:

    If the subject does not take anticoagulants, \< 1.5. If the subject is taking anticoagulants, INR \< 3.

  8. For fertile women, the serum pregnancy test must be negative prior to the enrollment into the study. Infertile women who have had natural (instinctive) menopause for at least 12 consecutive months prior to screening, with appropriate clinical manifestation (e.g. appropriate age, history of vasomotor symptoms), or have undergone bilateral oophorectomy, hysterectomy or bilateral tubal ligation more than 6 weeks prior to screening;
  9. Male or female subjects: Male subjects (whose partner is a fertile female) and fertile female subjects must use two acceptable methods of , including one barrier method, throughout the study period until 3 months after the last dose. Male subjects must also avoid donating sperm while participating in the study;
  10. Subjects must be able to swallow and absorb oral medication.

Exclusion criteria

Exclusion Criteria:

Subjects who meet any of the following will not be able to enter this study:

  1. Previous (≤3 years) or current existence of cancer histologically determined to be different from the study tumors, except for cervical carcinoma in situ, superficial non-invasive bladder tumor, or cured stage I non-melanoma skin cancer;
  2. Subjects carrying known major mutational driver genes other than RET gene, such as: EGFR, ALK, ROS1, etc.;
  3. Known severe allergy to the study drug or (microcrystalline cellulose);
  4. Severe diseases (including immune-related AEs from previous immuno-oncology therapy) or autoimmune diseases requiring chronic systemic therapy with doses (prednisone >10 mg/day or equivalent);
  5. Known malignant central nervous system diseases, except for neurologically stable and treated , which are defined as brain metastases that have been treated with surgery, surgery plus radiotherapy, or radiotherapy alone, with no signs of progression or hemorrhage within 14 days after treatment and all systemic corticosteroids discontinued within 14 days prior to the treatment.
  6. Medical history (within 6 months before treatment initiation) or evidence of pericarditis (of any grade) or pericardial effusion (≥ Grade 2);
  7. Medical history (within 6 months prior to initiation of therapy) or evidence of interstitial lung disease, radiation pneumonitis or idiopathic pulmonary fibrosis requiring steroid therapy, pleural or pericardial effusion requiring intervention such as drainage.
  8. Medical history (within 4 weeks after initiation of therapy) or evidence of active infection (≥ Grade 2);
  9. Medical history of positive serostatus for (HIV), virus (HBV), or virus (HCV) at any time before treatment:

    • Positive anti-HIV-1 or anti-HIV-2 antibodies,
    • or positive HBsAg
    • or positive anti-HCV antibody or quantifiable HCV-RNA.
    • For subjects with no previous result report, whether to conduct testing of serostatus during the screening period will be at the discretion of the investigator;
  10. Medical history (≤6 months before treatment) or evidence of any serious and/or uncontrolled medical condition or circumstances that the investigator and sponsor believe may affect the subject's participation in the study, for example:

    • Non-malignant disease that is not under control or the existing disease control of which could be jeopardized by the treatment in this study;
    • Malignant decompensated liver disease;
    • Severe gastrointestinal abnormalities or chronic diseases that affect absorption or intravenous nutritional needs, including inability to swallow formula products, delayed gastric emptying, chronic diarrhea associated with intestinal malabsorption, ulcerative colitis, or Crohn's disease requiring any dose level of steroids, nausea and vomiting, and/or prior surgery.
  11. With medical history (≤6 months before treatment initiation) or evidence of any of the following: acute myocardial infarction, unstable angina, coronary artery bypass grafting, cerebrovascular accident, or transient cerebral ischemic attack;
  12. Subjects with impaired cardiac function or cardiac diseases, including any of the following; congenital long syndrome;

    • Severe ventricular or supraventricular arrhythmia (in the absence of other cardiac abnormalities, atrial fibrillation patients with sinus arrhythmia or slow ventricular rate are eligible);
    • \<50% evaluated by ECHO or MUGA;
    • Resting bradycardia (\<50 beats per min) is determined by the mean of 3 heart rate values from three qualified screenings;
    • Other serious heart diseases, such as congestive heart failure of Class III-IV according to (NYHA);
  13. Subjects with a QT interval >470 ms corrected by the Fridericia formula (determined by the mean of 3 QTcF values from three qualified ECG screenings) during the screening phase;
  14. Medical history (≤6 months before treatment) or evidence of concomitant diseases that may prolong the QT interval according to the judgment of investigators and medical monitors;
  15. Medical history (≤6 months before treatment) or evidence of severe inflammatory or vascular ocular diseases (e.g., retinal vein occlusion);
  16. Subjects with unhealed toxicity higher than Grade 1 before treatment, except for those with hair loss (alopecia), Grade 2 neuropathy (if permitted by the investigator) or of 9-10 g/dL;
  17. Medical history (≤6 months before treatment) or evidence of malignant biliary obstruction, except for those with normal biliary stent function:
  18. Pregnant or breastfeeding women;
  19. History of bone marrow transplant or solid organ transplant;
  20. Use of systemic anticancer drugs (except for the antiandrogen therapy treating prostate cancer) or study drugs within 28 days prior to the first dose of FHND5071;
  21. Medical history of radiation therapy within 28 days prior to the first dose of FHND5071, or radiation therapy possibly required at any time until 30 days after the last dose of FHND5071, except for palliative radiation therapy limited to non-targeted lesions;
  22. Medical history (within 28 days after the treatment starts) or evidence of major surgery or trauma, or potentially required surgery during treatment (the severity will be determined by the investigator in consultation with the medical monitor) ;
  23. Medical history of transfusion of whole blood, red blood cells or within 2 weeks before the start of treatment;
  24. Patients using erythropoietin or granulocyte colony-stimulating factor (G-CSF), filgrastine or filgrastine for less than or equal to 2 weeks before treatment;
  25. Medical history of medication known to have risk of inducing torsades de pointes (arrhythmia due to drug-induced QTc prolongation) within 2 weeks before treatment until EOT follow-up.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    40mg

    FHND5071, 40mg, tablet, orally, once daily

    Drug: FHND5071

  • Experimental
    80mg

    FHND5071,80mg, tablet, orally, once daily

    Drug: FHND5071

  • Experimental
    160mg

    FHND5071, 160mg, tablet, orally, once daily

    Drug: FHND5071

  • Experimental
    240mg

    FHND5071, 240mg, tablet, orally, once daily

    Drug: FHND5071

  • Experimental
    320mg

    FHND5071, 320mg, tablet, orally, once daily

    Drug: FHND5071

  • Experimental
    400mg

    FHND5071, 400mg, tablet, orally, once daily

    Drug: FHND5071

Interventions

  • DrugFHND5071

    The proposed starting dose is 40 mg FHND5071 once daily (QD) orally (PO). For the purposes of this study treatment cycles will be 28 days or 4 weeks. FHND5071 will be administered orally in the morning following a fast of approximately 10 hours before dosing on PK collection days. Subjects will continue to fast for approximately 4 hours after the administration of FHND5071. On non-PK days the subjects will fast approximately 2 hours before FHND5071 and continue to fast for approximately 2 hours afterwards. Other dosing regimens may be considered based on the analysis of emerging PK, progressive disease, and/or safety data.

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting One or More Treatment-Emergent Adverse Events and Serious Adverse Events

    An Adverse Event is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A Serious Adverse Event (SAE) was any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

    Time frame: Baseline to 28 days after first dose of FHND5071 administration

07

Study locations

2 sites
  • Shanghai Chest Hospital
    Shanghai, China
  • Tianjin People's Hospital
    Tianjin, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2022 (actual). Primary completion is estimated for Dec 2023, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2023
First posted
Apr 19, 2023
StartActual
Jul 7, 2022
Primary completionEst.
Dec 31, 2023
CompletionEst.
Jul 31, 2024
Last update
Apr 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05818917
Responsible party
Sponsor
First posted
Apr 19, 2023
Start date
Jul 7, 2022
Primary completion
Dec 31, 2023 (estimated)
Completion
Jul 31, 2024 (estimated)
Last update
Apr 19, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion